Skip to main content

Tweets

Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/ruZM3Qftxb
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?

Dr. John Cush @RheumNow ( View Tweet )

3 months ago
RheumNow Live is 3 weeks away, and we can't wait to see you there! Why Attend In Person? ✔ Engage directly with faculty during live Q&A ✔ Network with peers who influence and lead in rheumatology ✔ Experience the energy, pace, and collaboration that can’t be replicated https://t.co/Do8srChyXW
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
The 2025 Rheumatology Year in Review The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders, ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines, and practices that https://t.co/gjNesm0AWO
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
ANAs and Autoantibodies https://t.co/PTdXPMCqjP https://t.co/Pbtgaod3uW
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
FDA & Administration are deregulating artificial intelligence & promote widespread use, includes use of wearables & other AI-enabled devices. Commissioner Marty Makary updated two guidance docs defining use general wellness devices, clinical decision support software https://t.co/KnkYqCiroa
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
QD Clinic: Sjogren's Beyond the Dryness Caitlin Hill, FNP, and David Maniscalco, MD, Santa Rosa, CA present this QD Clinic: Sjogren's - Beyond the Dryness. https://t.co/2U4Q2aRFec https://t.co/AGq36PT9iZ
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Spread of Psoriatic Disease from Skin to Joints Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD
Dr. John Cush @RheumNow ( View Tweet )
3 months ago
×